focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
I can't see any negatives behind it at all C7, and I'm sure that if any similar sized rival in this sector had had a comparable report put out we'd have been told volubly and repeatedly about it. At worst it's a positive summary, but seems very conveniently timed for more news imo.
Fair enough - so that sounds like you'd rate Vulpes' report around the 'vague ramping' area then.
Surprising that nobody has dismissed Vulpes' potential income forecasts as 'mad ramping', even though it is quite in tune with inanaco's expectations.
Morning CW - here's the text, note in particular the comment '...the government has already started efforts to search for private sector partners.' Also the comments re MaBs.
"The U.S. government is launching a $5B-plus program to accelerate the development of new coronavirus vaccines and treatments, officials from the Biden administration and the Department of Health and Human Services (HHS) confirmed Monday.
An HHS official said “Project Next Gen” will encourage public-private collaborations, similar to the “Operation Warp Speed” program that helped develop and distribute COVID-19 vaccines under former President Donald Trump in 2020.
“We’ve begun surveying the landscape out there — assessing what vaccine candidates are available, [and] moving through what exciting technologies are there,” The Washington Post reported quoting Dawn O’Connell, the assistant secretary for preparedness and response at the HHS.
O’Connell said that the government has already started efforts to search for private sector partners. “We’ve begun surveying the landscape out there — assessing what vaccine candidates are available, [and] moving through what exciting technologies are there,” he added.
“Project Next Gen” will focus on three main goals: speeding up the development of vaccines that produce mucosal immunity and those that target new COVID variants and other coronaviruses, and developing long-lasting monoclonal antibodies.
Leading COVID vaccine developers in the U.S.: Pfizer (NYSE:PFE)/BioNTech (BNTX), Moderna (MRNA), Johnson & Johnson (JNJ), and Novavax (NVAX).
Other vaccine makers: Merck (MRK), Sanofi (SNY), and GSK (GSK)
Developers of monoclonal antibodies against COVID: Eli Lilly (LLY)-AbCellera (ABCL), GSK(GSK)/ Vir Biotechnology (VIR), Roche (OTCQX:RHHBY) / Regeneron (REGN), and AstraZeneca (AZN)
“There’s a lot that government can do, the administration can do, to speed up those tools … for the American people,” Ashish Jha, the White House coronavirus coordinator, said.
According to Jha, the timeline for the market launch of new products will depend on multiple factors, including developers’ production plans and FDA reviews.
“The timelines are really going to be predicated on how quickly the scientific advancements continue, and how quickly we can study and measure the efficacy and safety of these products,” he explained.
The program marks the U.S. response to an evolving virus that made the first generation of mRNA-based COVID vaccines and all FDA-authorized monoclonal antibodies ineffective against new coronavirus strains."
I know the focus here is waiting to see what AACR might bring, but this link shows that there may yet be some interesting commercial potential for Covidity.
https://seekingalpha.com/news/3955481-us-launches-5b-program-develop-next-gen-covid-vaccines
Rob - Lindy's exact words were 'We’ve had to go longer and deeper, but when we get there it will be a bigger story because we will have achieved what nobody else has achieved and like everything when you’re the first it’s tougher.'
It took so much time to transcribe them, but interesting to note the exact words 'had to go longer and deeper' (rather than 'will have to') and 'when' and 'will' rather than 'if' and 'could.'
A comment better left in the board reserved for conspiracy theorists and ass toot posters for sure.
I stand corrected- it's 8.33 percent. Or call it a 91.66666667% failure rate if you like.
Val201 was phase 1/2, not phase 2, and aftercare conclusion of the 12 patient trial, some 2 and a half years ago, we were told 'Additional detailed analysis of the results will form the basis of peer-reviewed journal publications' but in all that time no peer reviewed publications have actually appeared.
The trial involved just 12 patients, one of whom (less than 8 percent) showed any significant response. Read the RNSs folks.
BioNtech - 'definitely one of the companies that we would engage with.' One of them...
Always interesting to see who is connected to who round here.
I was thinking 'Criminal Records Office.' Probably not that though.
Bear in mind in the last post that Lindy twice uses the word 'soon.' This was last November, so is 'soon' meaning 'within 6 months'? Could be, but then Scancell time moves slower than AIM investor time. Who knows, but personally I have decent hopes of AACR being a possible pivotal moment in one way or another.
Again, word for word, and a very pertinent and enduring question for many of us - (The shareholder's first name was given by LD but it is not relevant here I don't think)
‘Why do you believe the stock market doesn’t believe the good news of our story, and is it that we don’t have strong enough PR into that area of the advertising stock market?'
Lindy - 'We do not have an approved cancer vaccine, so there is a lot of cynicism out there that cancer vaccines can actually work, so for instance the deal we’ve done with the antibodies wasn’t even for a product, it was for a target and it was a great deal because there’s lots of antibodies already approved, so people know what they’re looking for, they know how they’re going to work, they feel confident, and comfortable with that whole area. There are still a lot of scepticisms about the vaccine. So therefore we need to go further, and that we already know. We’re in the clinic now, good news. We’re recruiting, good news. We’re getting T cell responses – good news. But we need clinical responses as well. First patient’s looking good but we need more than one patient to convince people. It will be the flip side – if this really is working and looking good there will be huge enthusiasm. We’ve had to go longer and deeper, but when we get there it will be a bigger story because we will have achieved what nobody else has achieved and like everything when you’re the first it’s tougher. At that point maybe we need different or better or stronger PR and I think there’s lots of people – Simon and his team amongst them waiting for that moment to go out and shout about it, it’s just that little bit too soon. But soon - we’re getting there definitely, that’s the exciting bit.'
(Note - WHEN we get there it WILL l be a bigger story because we WILL have achieved what nobody else has achieved)
And finally, a comment which has been posted before but bears repeating, from Martin Diggle - (in his words wearing his shareholder’s hat as opposed to his board hat) ‘It’s fair to say we’ve been invested in over a dozen life science companies in the last decade, and this is probably the most exciting thing we’ve ever seen, so well done.’
I found the recordings from the AGM buried in my phone's downloads, so have transcribed a few bits (unedited, to avoid accusations of cherry picking) -
Lindy on Glycans - ‘By making antibodies to the sugars that are likely to be just on cancer we’re getting superb specificity – we’re one of the very few companies in the world that can make these high affinity IGG antibodies that are really good at doing this, and that’s basically what Genmab were so excited about and that’s why we got the deal with Genmab.
Each of those sugars could be on lots of different proteins, on lots of different glycolipids and that means they can have potentially different mechanisms of action, so you could have an antibody binded to a sugar on a protien that’s internalised, and that’s a great way of delivering drugs, specifically to the cancer, and that’s what Genmab are really excited about and going to take forward.'
On SCLC - 'Our antibody binds beautifully to that tumour and not to (so far) any normal tissue – So this could be - and I’m always cautious about this - the Holy Grail of a completely cancer-specific antibody, and that’s why we’re taking this one into the clinic ourselves.'
Shareholder question re Biontech – 'regarding the T cells they wanted from the Modify trial – are they still interested in that and are you able to harvest those cells at this point?'
LD reply - 'The simple answer is yes they’re still interested and yes we can harvest them – they’re doing that as we speak... They’re even more interested in the vaccine though because that’s a simpler and cheaper way forward, so if we continue to get good clinical data they would be definitely one of the companies that we would engage with.'
Just a bit to contemplate in the run up to whatever AACR brings - earth-shattering, routine, or somewhere in between - we will find out whether we get all excited or just sit and watch the calendar move along.
The system also has trouble with that well known Lincolnshire steel town beginning with S.
WTP - it may look like a new lineup but it will most likely be some old faces with VPNs to get round the duplicate poster safeguards, or maybe the council have moved them to a new flat with a different ISP.
No problem - all will be revealed (or not!) at some point around the 18th. Fingers crossed.
It's the hope that while abstract details will be made public no earlier than 12:00 p.m. U.S. ET on Friday, April 14th, abstracts that are featured in the official AACR press program will be made publicly available at the date and time of presentation, either at the meeting or an official AACR press conference. So if Scancell's abstract doesn't appear with the rest, it could be kept as a proper headliner. Nice hope!
Bermuda - here's new thread title which may be more appropriate.